Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

Robin K. Avery(Johns Hopkins University), Francisco M. Marty(Brigham and Women's Hospital), Aimee K. Sundberg(Takeda (United States)), Emily A. Blumberg(University of Pennsylvania), Catherine Cordonnier(Leiden University Medical Center), Diana F. Florescu(Office of Infectious Diseases), Nassim Kamar, Martha Fournier(Takeda (United States)), Deepali Kumar(University Health Network), Roy F. Chemaly(The University of Texas MD Anderson Cancer Center), Rafael F. Duarte(Institut Català d'Oncologia), Sophie Alain(Université de Limoges), Genovefa A. Papanicolaou(Memorial Sloan Kettering Cancer Center), Johan Maertens(Universitair Ziekenhuis Leuven), Oliver Witzke(University of Duisburg-Essen), Jingyang Wu(Leeds Teaching Hospitals NHS Trust), Barbara D. Alexander(Duke Medical Center), Fernanda P. Silveira(University of Pittsburgh Medical Center)
Clinical Infectious Diseases
December 1, 2021
Cited by 299


Related Papers